<?xml version='1.0' encoding='utf-8'?>
<document id="27966237"><sentence text="Assessment of pharmacokinetic interaction between rilotumumab and epirubicin, cisplatin and capecitabine (ECX) in a Phase 3 study in gastric cancer."><entity charOffset="66-76" id="DDI-PubMed.27966237.s1.e0" text="epirubicin" /><entity charOffset="78-87" id="DDI-PubMed.27966237.s1.e1" text="cisplatin" /><entity charOffset="92-104" id="DDI-PubMed.27966237.s1.e2" text="capecitabine" /><entity charOffset="106-109" id="DDI-PubMed.27966237.s1.e3" text="ECX" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e0" e2="DDI-PubMed.27966237.s1.e0" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e0" e2="DDI-PubMed.27966237.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e0" e2="DDI-PubMed.27966237.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e0" e2="DDI-PubMed.27966237.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e1" e2="DDI-PubMed.27966237.s1.e1" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e1" e2="DDI-PubMed.27966237.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e1" e2="DDI-PubMed.27966237.s1.e3" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e2" e2="DDI-PubMed.27966237.s1.e2" /><pair ddi="false" e1="DDI-PubMed.27966237.s1.e2" e2="DDI-PubMed.27966237.s1.e3" /></sentence><sentence text="Rilotumumab is a fully human monoclonal antibody investigated for the treatment of MET-positive gastric cancer" /><sentence text=" The aim of this study was to evaluate the potential pharmacokinetic (PK)-based drug-drug interaction (DDI) between rilotumumab and epirubicin (E), cisplatin(C) and capecitabine (X)"><entity charOffset="132-142" id="DDI-PubMed.27966237.s3.e0" text="epirubicin" /><entity charOffset="165-177" id="DDI-PubMed.27966237.s3.e1" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.27966237.s3.e0" e2="DDI-PubMed.27966237.s3.e0" /><pair ddi="false" e1="DDI-PubMed.27966237.s3.e0" e2="DDI-PubMed.27966237.s3.e1" /></sentence><sentence text="" /><sentence text="This was a Phase 3 double-blind, placebo-controlled study, in which rilotumumab, epirubicin and cisplatin were administered intravenously at 15 mg kg-1 , 50 mg m-2 , and 60 mg m-2 Q3W, respectively, while capecitabine was given orally at 625 mg m-2 twice daily"><entity charOffset="81-91" id="DDI-PubMed.27966237.s5.e0" text="epirubicin" /><entity charOffset="96-105" id="DDI-PubMed.27966237.s5.e1" text="cisplatin" /><entity charOffset="205-217" id="DDI-PubMed.27966237.s5.e2" text="capecitabine" /><pair ddi="false" e1="DDI-PubMed.27966237.s5.e0" e2="DDI-PubMed.27966237.s5.e0" /><pair ddi="false" e1="DDI-PubMed.27966237.s5.e0" e2="DDI-PubMed.27966237.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27966237.s5.e0" e2="DDI-PubMed.27966237.s5.e2" /><pair ddi="false" e1="DDI-PubMed.27966237.s5.e1" e2="DDI-PubMed.27966237.s5.e1" /><pair ddi="false" e1="DDI-PubMed.27966237.s5.e1" e2="DDI-PubMed.27966237.s5.e2" /></sentence><sentence text=" Rilotumumab PK samples were taken at pre-dose and at the end-of-infusion from all patients in cycles 1, 3, 5 and 7" /><sentence text=" ECX PK samples were taken in cycle 3 from patients who participated in the intensive PK assessment"><entity charOffset="1-12" id="DDI-PubMed.27966237.s7.e0" text="ECX" /></sentence><sentence text=" ECX PK was assessed by non-compartmental (NCA) analyses and PK parameters were compared between two arms"><entity charOffset="1-3" id="DDI-PubMed.27966237.s8.e0" text="ECX" /></sentence><sentence text=" Rilotumumab PK was assessed by comparing the observed rilotumumab serum concentrations with model-predicted concentrations using a population PK model developed from previous Phase 1 and Phase 2 studies" /><sentence text="" /><sentence text="The study enrolled 609 patients" /><sentence text=" ECX plasma concentrations in the presence and absence of rilotumumab were similar, as demonstrated by the geometric mean ratios for Cmax and AUC, which were close to 1"><entity charOffset="1-3" id="DDI-PubMed.27966237.s12.e0" text="ECX" /></sentence><sentence text="0, suggesting ECX PK was not affected by co-administration of rilotumumab"><entity charOffset="14-16" id="DDI-PubMed.27966237.s13.e0" text="ECX" /></sentence><sentence text=" The observed rilotumumab serum concentrations were similar to the values predicted by population PK modelling on the basis of a prediction-corrected visual predictive check, indicating rilotumumab exposure was not affected by co-administration of ECX"><entity charOffset="248-250" id="DDI-PubMed.27966237.s14.e0" text="ECX" /></sentence><sentence text="" /><sentence text="The results suggest lack of PK-based DDI between rilotumumab and ECX"><entity charOffset="65-67" id="DDI-PubMed.27966237.s16.e0" text="ECX" /></sentence><sentence text="" /></document>